Please use this identifier to cite or link to this item: https://doi.org/10.3324/haematol.2018.201483
Title: Proteolysis targeting chimeric molecules as therapy for multiple myeloma: Efficacy, biomarker and drug combinations
Authors: Lim, S.L.
Damnernsawad, A.
Shyamsunder, P. 
Chng, W.J. 
Han, B.C.
Xu, L. 
Pan, J.
Pravin, D.P. 
Alkan, S.
Tyner, J.W.
Koeffler, H.P. 
Issue Date: 2019
Publisher: Ferrata Storti Foundation
Citation: Lim, S.L., Damnernsawad, A., Shyamsunder, P., Chng, W.J., Han, B.C., Xu, L., Pan, J., Pravin, D.P., Alkan, S., Tyner, J.W., Koeffler, H.P. (2019). Proteolysis targeting chimeric molecules as therapy for multiple myeloma: Efficacy, biomarker and drug combinations. Haematologica 104 (6) : 1209-1220. ScholarBank@NUS Repository. https://doi.org/10.3324/haematol.2018.201483
Rights: Attribution-NonCommercial 4.0 International
Abstract: Proteolysis targeting chimeric molecule ARV 825 causes ubiquitination of bromodomains resulting in their efficient degradation by proteasome activity. Bromodomain degradation down-regulates MYC transcription contributing to growth inhibition of various human cancers. We examined the therapeutic potential of ARV 825 against multiple myeloma (MM) cells both in vitro and in vivo. In a dose-dependent manner, ARV 825 inhibited proliferation of 13 human MM cell lines and three fresh patient samples, and was associated with cell cycle arrest and apoptosis. ARV 825 rapidly and efficiently degraded BRD 2 and BRD 4. Sensitivity of MM cells to ARV 825 was positively correlated with cereblon levels. RNA sequencing analysis showed important genes such as CCR1, RGS, MYB and MYC were down-regulated by ARV 825. A total of 170 small molecule inhibitors were screened for synergy with ARV 825. Combination of ARV 825 with inhibitor of either dual PI3K/mTOR, CRM1, VEGFR, PDGFR?/b, FLT3, IGF-1R, protein kinase C, CBP-EP300 or JAK1/2 showed synergistic activity. Importantly, ARV 825 significantly inhibited the growth of MM xenografts and improved mice survival. Taken together, our results, in conjunction with recently published findings, provide a rationale for investigating the efficacy of ARV 825 for MM, use of cereblon as a biomarker for therapy of MM patients, and the combination of ARV 825 with small molecule inhibitors to improve the outcome of MM patients. © 2019 Ferrata Storti Foundation.
Source Title: Haematologica
URI: https://scholarbank.nus.edu.sg/handle/10635/209622
ISSN: 0390-6078
DOI: 10.3324/haematol.2018.201483
Rights: Attribution-NonCommercial 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3324_haematol_2018_201483.pdf3.1 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

28
checked on Feb 2, 2023

Page view(s)

79
checked on Feb 2, 2023

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons